Analyst Price Targets — OCS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 1, 2026 6:12 pm | — | Robert W. Baird | $38.00 | $14.51 | TheFly | Oculis price target lowered to $38 from $49 at Baird |
| June 1, 2026 11:28 am | — | Guggenheim | $45.00 | $22.71 | TheFly | Oculis price target lowered to $45 from $75 at Guggenheim |
| June 1, 2026 11:28 am | — | Needham | $38.00 | $22.71 | TheFly | Oculis price target lowered to $38 from $46 at Needham |
| June 1, 2026 10:25 am | — | H.C. Wainwright | $26.00 | $22.71 | TheFly | Oculis price target lowered to $26 from $47 at H.C. Wainwright |
| May 20, 2026 8:14 pm | — | Guggenheim | $75.00 | $27.91 | TheFly | Oculis initiated with a Buy at Guggenheim |
| May 12, 2026 4:14 pm | — | H.C. Wainwright | $47.00 | $30.30 | TheFly | Oculis price target raised to $47 from $44 at H.C. Wainwright |
| March 4, 2026 9:46 pm | Annabel Samimy | Stifel Nicolaus | $50.00 | $27.72 | StreetInsider | Oculis Holding AG (OCS) PT Raised to $50 at Stifel |
| December 19, 2025 12:42 pm | Annabel Samimy | Stifel Nicolaus | $40.00 | $20.98 | StreetInsider | Oculis Holding AG (OCS) PT Raised to $40 at Stifel; An 'Under-the-Radar Name' |
| October 8, 2025 11:08 am | — | Chardan Capital | $51.00 | $19.06 | TheFly | Oculis price target raised to $51 from $33 at Chardan |
| October 7, 2025 10:13 am | Yi Chen | H.C. Wainwright | $36.00 | $18.56 | TheFly | Oculis price target raised to $36 from $33 at H.C. Wainwright |
Latest News for OCS
The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announces that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis (ON).
ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
The average of price targets set by Wall Street analysts indicates a potential upside of 187.8% in Oculis Holding AG (OCS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”), a private translational neuroscience R&D company, today announced that Oculis and Accure have…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for OCS.
Senate Trading
No Senate trades found for OCS.
U.S. House Trading
No House trades found for OCS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.